Compare HRMY & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | PEB |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2020 | 2009 |
| Metric | HRMY | PEB |
|---|---|---|
| Price | $38.04 | $19.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | ★ $48.25 | $19.32 |
| AVG Volume (30 Days) | 750.6K | ★ 1.9M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 0.21% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | $868,453,000.00 | ★ $1,475,544,000.00 |
| Revenue This Year | $18.62 | $0.56 |
| Revenue Next Year | $13.23 | $2.02 |
| P/E Ratio | $20.62 | ★ N/A |
| Revenue Growth | ★ 21.51 | 1.53 |
| 52 Week Low | $25.81 | $9.99 |
| 52 Week High | $43.49 | $19.96 |
| Indicator | HRMY | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 61.73 |
| Support Level | $37.48 | $17.50 |
| Resistance Level | $39.35 | $19.73 |
| Average True Range (ATR) | 1.28 | 0.50 |
| MACD | -0.24 | 0.05 |
| Stochastic Oscillator | 50.52 | 69.52 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under the Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.